What type of study is this?

This is a Cohort Study study (also classified as: Quantitative Study).

September 20, 2025Open Access

Figure 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer

Key Points

Patients with immune-related adverse events had different survival outcomes compared to those without them.
Kaplan–Meier curves indicated variations in overall survival and progression-free survival between groups.
Multivariable analysis identified additional prognostic factors affecting survival outcomes in the ICI–TKI group.
The study emphasizes the importance of considering immune-related adverse events in treatment evaluations.

Abstract

Survival outcomes and multivariable analysis of prognostic factors in the ICI–TKI group. A, Kaplan–Meier curves for OS and PFS. The results of a survival analysis conducted on the ICI–TKI group with and without irAEs. The red line represents the patient group without irAEs, and the blue line represents the patient group with irAEs. B, Multivariable analysis of OS and PFS of the ICI–TKI group. NA, not available.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Bunpei Isoda

Masanobu Shiga

Shuya Kandori

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Figure 3 from Prognostic Impact of Immune-Related Adverse Events on Combination Immune Checkpoint/Tyrosine Kinase Inhibition for Metastatic Renal Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study